Island Pharmaceuticals (ASX: ILA) has entered into a three-year Cooperative Research and Development Agreement (CRADA) with USAMRIID and The Geneva Foundation to accelerate Galidesivir for Marburg Virus Disease (MVD), building on recent US Food and Drug Administration (FDA) alignment and funding milestones.
The agreement specifically focuses on developing Galidesivir for MVD under the FDA Animal Rule pathway.
Key activities under the CRADA include the design and execution of non-human primate (NHP) studies, crucial steps required for progressing towards a New Drug Application (NDA) approval.
The collaboration also includes an option for expansion beyond the initial three-year term.
USAMRIID and Geneva Foundation Roles
USAMRIID brings valuable prior experience to the collaboration, having historically supported Galidesivir development.
This includes conducting NHP studies for both Ebola and Marburg viruses.
The Geneva Foundation plays a critical role by offering capabilities to accelerate government programs.
The foundation manages approximately 383 million USD in annual research funding and collaborates extensively with academic and industry networks to support biodefense initiatives.
This partnership effectively leverages established biodefense infrastructure and funding networks to propel Galidesivir development.
Galidesivir's Regulatory and Funding Context
This latest agreement follows previous positive developments for Galidesivir that saw the FDA confirm an Animal Rule development pathway, significantly de-risking the program by providing a clear regulatory roadmap.
Earlier this year, Island Pharmaceuticals secured a $9 million placement from institutional and sophisticated investors.
This funding was earmarked to fully finance the two-stage Galidesivir Animal Rule development, including manufacturing for clinical and regulatory use, and other essential regulatory and preclinical work.
The ultimate goal remains NDA submission under the Animal Rule, with the potential for US government procurement and a valuable Priority Review Voucher.
Advances Galidesivir Pathway
Island Pharmaceuticals' new CRADA with US government entities marks a substantial step in advancing Galidesivir for Marburg Virus Disease under the FDA Animal Rule.
Combined with prior funding and regulatory clarity, this collaboration strengthens the program's de-risking and development trajectory.
